Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Clinical trial NCT05292391 · COMPLETED
Trial details
- NCT number
- NCT05292391
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-23
- Primary completion
- 2024-03-19
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.